The Neurobiology of Cognition in Schizophrenia
J Clin Psychiatry 2006;67(9):e11
© Copyright 2016 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Cognitive dysfunction in schizophrenia differs from cognitive dysfunction in
neurodegenerative illnesses because it is associated with neuronal dysfunction
and not neurodegeneration. Pharmacologically, potential targets for developing
treatments may differ from cognition in dementing disorders. Several putative
molecular targets for treating cognition in schizophrenia show promise, such as
treatments that act on the D1 receptor of the dopamine system; the
and 5HT6, receptors of the
serotonin system; and ampakines, Glycine/D-cycloserine, D-serine, and mGluR 2/3
agonists of the glutamatergic system. Other receptors associated with
improvement in cognition include nicotinic and muscarinic receptors, and the
subunit receptor of the brain GABA system. Domain treatment of
schizophrenia is a new method of treating schizophrenia that involves treating a
single domain of dysfunction at a time.
See the entire activity.